Circassia Pharmaceuticals

Circassia sets platform for strong growth in 2019 after period of consolidation

Steve Harris, chief executive of Circassia Pharmaceuticals PLC (LON:CIR), talks Proactive London's Andrew Scott through the group's 2018 results and the first quarter of this year.

Circassia's taken full commercial control of Tudorza, a treatment for chronic obstructive pulmonary disease (COPD), while its sales of its asthma product NIOX continued to grow.

They've also added AirNOvent, a late-stage nitric oxide candidate, to its pipeline, which, when approved, should aid the sales effort.

Quick facts: Circassia Pharmaceuticals

Price: £0.19

Market: LSE
Market Cap: £69.97 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Circassia Pharmaceuticals named herein, including the promotion by the Company of Circassia Pharmaceuticals in any Content on the Site, the...



Full interview: New Pacific Metals releases metallurgical testing from...

New Pacific Metals (CVE: NUAG) President Gordon Neal sat down with Steve Darling from Proactive Vancouver to talk about the latest work that was done on their Silver Sand Project in Bolivia. Neal talked about some of the results from testing and also about their drill program. Neal telling...

2 days, 1 hour ago


Director/PDMR Shareholding

2 days, 2 hours ago

Total Voting Rights

3 weeks, 4 days ago

Holding(s) in Company

on 07/22/2019

Holding(s) in Company

on 07/09/2019

Holding(s) in Company

on 07/08/2019

Holding(s) in Company

on 07/05/2019

Holding(s) in Company

on 07/02/2019

2 min read